Literature DB >> 34162785

Pathological and immunohistochemical features of 45 cases of feline meningioma.

Ryo Saito1, James K Chambers1, Takuya E Kishimoto1, Kazuyuki Uchida1.   

Abstract

Meningioma is the most common primary brain tumor in cats, although there are few reports about their pathological features. To investigate the histopathological subtypes and immunohistochemical features including expression of cytokeratin and cell adhesion molecules, 45 cases of feline meningioma were examined. The mean age was 12.5 years (range 6-21 years). No statistically significant sex predilection was observed. Regarding the anatomical location of meningioma, tumors mostly developed in the cerebrum, followed by spinal cord and cerebellum, and multiple meningioma was observed in one cat. Microscopically, linear or focal mineralization was observed in 40 cases and cholesterol cleft was observed in 14 cases. Based on histopathological subtypes, there were 15 fibrous, 22 transitional, 2 meningothelial, 5 atypical, and 1 anaplastic meningiomas. These subtypes are classified into grade 1 (39 cases), grade 2 (5 cases), and grade 3 (1 case). There was no significant difference in the Ki-67 index among histological subtypes or grades. Immunohistochemically, the tumor cells were positive for cytokeratin in 5 cases (12.8%), vimentin in 17 cases (43.6%), E-cadherin in 36 cases (92.3%), β-catenin in 21 cases (53.8%), and N-cadherin in 1 case (2.6%), demonstrating the utility of E-cadherin-immunohistochemistry for the diagnosis of feline meningiomas.

Entities:  

Keywords:  E-cadherin; cat; immunohistochemistry; meningioma; proliferation index

Year:  2021        PMID: 34162785     DOI: 10.1292/jvms.21-0258

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  1 in total

1.  Encephalic meningioangiomatosis in a cat.

Authors:  Megan P Corbett; Brianna L Kopec; Marc Kent; Daniel R Rissi
Journal:  J Vet Diagn Invest       Date:  2022-07-14       Impact factor: 1.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.